Latest News and Press Releases

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

Heartland Oncology and Hematology Oncologist Named 2025 Advocacy Champion by the Association for Clinical Oncology (ASCO)

GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference...

Remedy Plan has raised an $18M insider round to advance their lead asset, RPT1G, into a Phase 1/2 clinical trial in patients with AML and high-risk MDS

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

American Oncology Network Appoints Terri Casey as Chief Human Resources Officer

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and expansion trial.GEN-1013 was studied in aggressive murine cancer models...

Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines...